生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团

华福证券2025-06-23

（以下内容从华福证券《生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团》研报附件原文摘录）专题：体内CAR-T一旦被证明安全、有效，将带来细胞治疗范式的转变，海外CapstanTherapeutics、EsoBiotec、Umoja等Biotech已有产品启动临床1期，25年H2有望有初步疗效验证数据读出。艾伯维、阿斯利康等多个制药巨头已通过合作/收购布局体内CAR-T赛道。国内...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2545187754?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-23 18:07","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2545187754","market":"us","top_or_hot":-1,"title":"生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团","media":"华福证券","content":"<div>\n<p>（以下内容从华福证券《生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团》研报附件原文摘录）专题：体内CAR-T一旦被证明安全、有效，将带来细胞治疗范式的转变，海外CapstanTherapeutics、EsoBiotec、Umoja等Biotech已有产品启动临床1期，25年H2有望有初步疗效验证数据读出。艾伯维、阿斯利康等多个制药巨头已通过合作/收购布局体内CAR-T赛道。国内...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506231808059527dd22&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-23 18:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506231808059527dd22&s=b><strong>华福证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（以下内容从华福证券《生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团》研报附件原文摘录）专题：体内CAR-T一旦被证明安全、有效，将带来细胞治疗范式的转变，海外CapstanTherapeutics、EsoBiotec、Umoja等Biotech已有产品启动临床1期，25年H2有望有初步疗效验证数据读出。艾伯维、阿斯利康等多个制药巨头已通过合作/收购布局体内CAR-T赛道。国内...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506231808059527dd22&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02105","symbol_name":"来凯医药-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506231808059527dd22&s=b","article_id":"2545187754","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506231808059527dd22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2545187754","pubTimestamp":1750673278,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"艾伯维、阿斯利康等多个制药巨头已通过合作/收购布局体内CAR-T赛道。石药集团自主研发的mRNA-LNP的自体CAR-T疗法进入临床，体内CAR-T的布局亦可期待。全球自体CAR-T细胞疗法全球销售额2024年合计超45亿美金，制造过程繁琐、可及性低和价格昂贵的缺点限制其应用。实现体内CAR-T疗法的核心挑战，在于如何将CAR构建体精准、高效且安全地递送至目标T细胞。慢病毒载体可将CAR基因永久整合到宿主T细胞的基因组中。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","02105":"来凯医药-B","BK4588":"碎股","ZLAB":"再鼎医药","ONC":"百济神州","BK4548":"巴美列捷福持仓","06160":"百济神州","09688":"再鼎医药","BK4022":"陆运","BK4139":"生物科技","BK4531":"中概回港概念","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK4230":"旅客陆运","09926":"康方生物","01672":"歌礼制药-B","03681":"中国抗体-B","CAR":"安飞士","01801":"信达生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"Biomedicine: In vivo CAR-T: The global competition has started, pay attention to Genting Xinyao and CSPC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":0.9,"CAR":1,"02105":0.9,"06160":0.9,"09688":0.9,"01801":0.9,"ONC":0.9,"01672":0.9,"09926":0.9,"03681":0.9,"ZLAB":0.9},"content_text":"（以下内容从华福证券《生物医药：体内CAR-T：全球竞赛已打响，关注云顶新耀和石药集团》研报附件原文摘录）专题：体内CAR-T一旦被证明安全、有效，将带来细胞治疗范式的转变，海外CapstanTherapeutics、EsoBiotec、Umoja等Biotech已有产品启动临床1期，25年H2有望有初步疗效验证数据读出。艾伯维、阿斯利康等多个制药巨头已通过合作/收购布局体内CAR-T赛道。国内企业中云顶新耀mRNA自体生成CAR-T项目已取得多项临床前验证，在人源化小鼠肿瘤模型中实现了有效靶细胞清除，可期待临床前完整数据。石药集团自主研发的mRNA-LNP的自体CAR-T疗法进入临床，体内CAR-T的布局亦可期待。全球自体CAR-T细胞疗法全球销售额2024年合计超45亿美金，制造过程繁琐、可及性低和价格昂贵的缺点限制其应用。体内制造CAR-T细胞的核心优势在于显著简化流程并降低成本、根据Nature杂志预测显示，单次治疗的成本可能比目前的商业CAR-T疗法低一个数量级。实现体内CAR-T疗法的核心挑战，在于如何将CAR构建体精准、高效且安全地递送至目标T细胞。目前主要形成了慢病毒载体与RNA递送两大技术路线。慢病毒载体可将CAR基因永久整合到宿主T细胞的基因组中。其最大优势在于可实现持久的CAR表达，疗效可能维持数年，缺点可能是靶向性不足，有整合基因致瘤的风险。RNA递送派采用LNP等非病毒载体，将编码CAR蛋白的mRNA递送至T细胞胞质。mRNA不整合入基因组，仅在胞质内短暂指导CAR蛋白合成。核心优势在于安全性高（规避基因组整合及永久性基因改变风险）和可控性好——若出现严重副作用，停药后CAR活性可数天内消失。复盘及中长期投资策略：本周行业事件主要有：1、第85届美国糖尿病协会（ADA）期间多款创新减肥药物和减重创新机制数据披露，包括多肽GLP-1R/AMYR激动剂、ACVR2A单抗、小分子线粒体丙酮酸转运载体（MPC）抑制剂、AMYR激动剂等；2、先声再明与NextCure就CDH6ADC新药达成战略合作，总金额7.5亿美金。行情复盘及解读：创新药5月中旬以来受到三生制药重大授权积极影响，有大品种海外授权预期的企业涨幅比较突出，叠加周一先声药业合作授权首付款及总金额对比之前三生制药等授权金额较小，市场情绪有所调整，短期创新药波动可能较大。我们建议积极拥抱龙头和一/二线标的，尤其是港股创新药龙头（含Pharma），行业催化方面关注6月20-23日举办的美国糖尿病ADA大会以及后续中报业绩表现亮眼的企业。我们认为中国创新药正在“量变引起质变”，看好创新药5-10年的产业趋势，中长期我们建议关注如下方向：1）临床数据/商业化放量驱动的创新药：百济神州/信达生物/康方生物/科伦博泰/映恩生物/再鼎医药/云顶新耀/泽璟制药/迪哲/艾力斯；2）潜在BD可能得大品种：信达生物/康方生物/新诺威/益方生物/一品红/复宏汉霖/舒泰神/华纳药厂/基石药业；3）Pharma创新转型后的价值重估：恒瑞医药/石药集团/三生制药/康弘药业/东阳光长江药业/康哲药业/远大医药/奥赛康/信立泰/先声制药；4）价值发现/静待花开组合：歌礼制药/来凯医药/苑东生物/科济药业/华领医药/中国抗体等。创新药本周建议关注组合：百济神州、信达生物、康方生物、石药集团、再鼎医药、云顶新耀、歌礼制药、来凯医药、中国抗体。风险提示：行业需求不及预期风险、公司业绩不及预期风险、市场竞争加剧风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2545187754","isCrawlerRequest":true}